Whole-body hyperthermia as an adjuvant to treatment with platinum complexes with or without etanidazole in mice bearing the Lewis lung carcinoma or the FSaLL fibrosarcoma

References

• Adams G. E., Ahmed I., Sheldon P. W., et al. Radiation sensitization and chemo-potentiation: RSU-1069, a compound more effective than misonidazole in vitro and in vivo. British Journal of Cancer 1984; 49: 5571–5577
   Web of Science ®Google Scholar
• Baba H., Siddik Z. H., Strebel F. R., Jenkins G. N., Bull J. M. C. Increased therapeutic gain of combined cis-diamminedichloroplatinum(II) and whole body hyperthermia by optimal heat/drug scheduling. Cancer Research 1989; 39: 7041–7044
   Google Scholar
• Baba H., Stephens L. C., Strebel F. R., Siddik Z. H., Newman R. A., Ohno S., Bull J. M. C. Protective effect of ICRF-187 against normal tissue injury induced by adriamycin in combination with whole body hyperthermia. Cancer Research 1991; 51: 3568–3577
   PubMed Web of Science ®Google Scholar
• Bull J. M. A review of systemic hyperthermia. Frontiers in Radiation Therapy and Oncology 1984; 18: 171–176
   PubMedGoogle Scholar
• Bull J. M. C., Strebel F. R., Sunderland B. A., Bulger R. E., Edwards M., Siddik Z. H., Newman R. H. 0-β-Hydroxyethyl)-rustoside-mediated protection of renal injury associated with cis-diamminedichloroplatinum(II)/hyperthermia treatment. Cancer Research 1988; 48: 2239–2244
   PubMed Web of Science ®Google Scholar
• Chaplin D. J., Durand R. E., Stratford I. J., Jenkins T. C. The radiosensitizing and toxic effects of RSU-1069 on hypoxic cells in a murine tumor. International Journal of Radiation Oncology, Biology and Physics 1986; 12: 1091–1095
   PubMed Web of Science ®Google Scholar
• Clement J. J., Gorman M. S., Wodinsky I., Catane R., Johnson R. K. Enhancement of antitumor activity of alkylating agents by the radiation sensitizer misonidazole. Cancer Research 1980; 40: 4165–4172
   PubMed Web of Science ®Google Scholar
• Cronaw L. H., Jr, Bourke D. L., Bull J. M. General anethesia for whole-body hyperthermia. Cancer Research 1984; 44(Suppl.)4873s–4877s
   Google Scholar
• Dahl O. Interaction of hyperthermia and chemotherapy. Recent Results in Cancer Research 1987; 107: 157–169
   Google Scholar
• Daly J. M., Smith G., Frazier O. H., Dudrick S. J., Copeland E. M. Effects of systemic hyperthermia and intrahepatic infusion with 5-fluorouracil. Cancer 1982; 49: 112–115
   Web of Science ®Google Scholar
• Engelhardt R. Hyperthermia and drugs. Recent Results in Cancer Research 1987; 104: 136–203
   PubMedGoogle Scholar
• Engelhardt R. Summary of recent clinical experience in whole-body hyperthermia combined with chemotherapy. Application of Hyperthermia in the Treatment ofCancer, R. D. Issels, W. Wilmanns, 1988; 200–204
   Google Scholar
• Fowler J. F. Chemical modifiers of radiosensitivity-theory and reality: a review. International Journal of Radiation Oncology, Biology and Physics 1985; 11: 665–674
   PubMed Web of Science ®Google Scholar
• Frank A. J. Misonidazole and other hypoxia markers. Metabolism and applications. International Journal of Radiation Oncology, Biology and Physica 1986; 12: 1195–1202
   PubMed Web of Science ®Google Scholar
• Herman T. S., Zukoski C. F., Anderson R. M., Hutter J. J., Blitt C. D., Malone J. M., Larson D. F., Dean J. C., Roth H. B. Whole-body hyperthermia and chemotherapy for treatment of patients with advanced, refractory malignancies. Cancer Treatment Reports 1982; 66: 259–265
   PubMedGoogle Scholar
• Herman T. S., Teicher B. A., Cathcart K. N. S., Kaufmann M. E., Lee J. B., Lee M. Effect of hyperthermia on cis-diamminedichloroplatinum(II) (rhodamine 123)2[tetrachloroplatinum(II)] in a human squamous carcinoma cell line and a cis-diamminedichloroplatinum(II)-resistant subline. Cancer Research 1988a; 48: 5101–5105
   PubMed Web of Science ®Google Scholar
• Herman T. S., Teicher B. A., Chan V., Collins L. S., Kaufmann M. E., Loh C. The effect of hyperthermia on the action of cis-diamminedichloroplatinum(II), rhodamine-1232[tetrachloroplatinum(II)], Rhodamine, 123 and potassium tetrachloroplatinate in vitro and in vivo. Cancer Research 1988b; 48: 2335–2341
   PubMed Web of Science ®Google Scholar
• Hinkelbein W., Menger D., Birmelin M., Engelhardt R. The influences of whole-body hyperthermia on myelotoxicity of doxorubicin and irradiation in rats. Proceedings of the 4th International Symposium on Hyperthermic Oncology, AarhusDenmark, 1984. Vol. 1: 281–283
   Google Scholar
• Klein M. K., Dewhirst M. W., Fuller D. J. M. Whole body hyperthermia and heat sensitizing drugs: a pilot study in canine lymphoproliferative disease. International Journal of Hyperthermia 1987; 3: 187–198
   PubMed Web of Science ®Google Scholar
• Magin R. L. Hyperthermia and chemotherapy: When will they be used in the clinical treatment of cancer. European Journal of Cancer and Clinical Oncology 1983; 19: 1655–1658
   PubMedGoogle Scholar
• Mella O., Eriksen R., Dahl O., Laerum O. D. Acute systemic toxicity of combined cis-diamminedichloroplatinum and hyperthermia in the rat. European Journal of Cancer and Clinical Oncology 1987; 23: 365–313
   PubMedGoogle Scholar
• Meyer J. L., Kapp D. S., Fessenden P., Hahn G. H. Hyperthermic oncology: Current biology, physics and clinical results. Pharmacology and Therapeutics 1989; 42: 251–288
   PubMed Web of Science ®Google Scholar
• Novotney C. A., Page R. L., Macy D. W., Dewhirst M. W., Ogilvie G. K., Withrow S. J., McEntee M. C., Heidner G. L., Allen S. A., Thrall D. E., Gillette E. L. Phase I evaluation of doxorubicin and whole body hyperthermia in dogs with lymphosarcoma. Journal of Veterinary Internal Medicine 1991, In press
   Web of Science ®Google Scholar
• Ohno S., Siddik Z. H., Baba H., Stephens L. C., Strebel F. R., Wondergem J., Khokhar A. R., Bull J. M. C. Effect of carboplatin combined with whole body hyperthermia on normal tissue and tumor in rats. Cancer Research 1991; 51: 2994–3000
   PubMed Web of Science ®Google Scholar
• Ostrow S., Van Echo D., Egorin M., Whitacre M., Grochow L., Aisner J., Colvin O. M., Bachur N., Wiernik P. H. Cyclophosphamide pharmacokinetics in patients receiving whole-body hyperthermia. National Cancer Institute Monograph 1982; 61: 401–403
   Google Scholar
• Page R. L., Macy D. W., Ogilvie G. K., Dewhirst M. W., Thrall D. E., Rosner G., Withrow S. J., McEntee M. C., Cline J. M., Novotney C. A., Gillette E. Phase III evaluation of doxorubicin and whole body hyperthermia in dogs with lymphoma. International Journal of Hyperthermia 1991a; 8: 187–198
   Web of Science ®Google Scholar
• Page R. L., Riviere J. E., Heidner G. L., McEntee M. C., Thrall D. E. Effect of temperature on cisplatin and carboplatin pharmacokinetic disposition in dogs. Proceedings, 5th International Symposium on Hyperthermic Oncology, KyotoJapan, 1988; Vol. II: 499–501
   Google Scholar
• Page R. L., Thrall D. E., Dewhirst M. W., Macy D. W., George S. L., McEntee M. C., Heidner G. L., Novotney C. A., Allen S. A., Withrow S. J., Ogilvie G. K., Gillette E. L. Phase I study of melphalan and whole body hyperthermia in dogs with malignant melanoma. International Journal of Hyperthermia 1991b; 7: 559–566
   PubMed Web of Science ®Google Scholar
• Price G. S., Page R. L., Hoopes P. J., Riviere J. E., Aucoin D. E., Thrall D. E. Phase I and pharmacokinetic study of lonidamine in normal dogs. Proceedings, North American Hyperthermia Group Meeting. 1988; 38
   Google Scholar
• Price G. S., Page R. L., Riviere J. E., Cline J. M., Frazier D. L., Thrall D. E. The effect of whole body hyperthermia on the pharmacokinetics and toxicity of doxorubicin and lonidamine in normal dogs. Proceedings, North American Hyperthermia Group Meeting. 1990; 27
   Google Scholar
• Price G. S., Page R. L., Riviere J. E., Cline M. J., Thrall D. E. Pharmacokinetics and toxicity of intravenous lonidamine and whole body hyperthermia in normal dogs. Proceedings, North American Hyperthermia Group Meeting. 1989; 69
   Google Scholar
• Rice L., Urano V., Suit H. D. The radiosensitivity of a murine fibrosarcoma as measured by three cell survival assays. British Journal of Cancer 1980; 41(Suppl. IV)240–244
   Google Scholar
• Riviere J. E., Page R. L., Dewhirst M. W., Thrall D. E. Effect of hyperthermia on cisplatin pharmacokinetics in normal dogs. International Journal of Hyperthermia 1986; 2: 351–358
   PubMedGoogle Scholar
• Riviere J. E., Page R. L., Rogers R. A., Chang S. K., Thrall D. E. Nonuniform alteration of cis-diammindichloroplatinum tissue distribution in dogs undergoing whole body hyperthermia. Cancer Research 1990; 50: 2075–2080
   PubMed Web of Science ®Google Scholar
• Robins H. I. Role of whole-body hyperthermia in the treatment of neoplastic disease: Its current status and future prospects. Cancer Research 1984; 44(Suppl.)4878s–4883s
   Google Scholar
• Robins H. I., Steeves R. A., Shecterle L. M., Martin P. A., Miller K. A., Paliwal B., Neville A. J., Dennis W. H. WBH (41–42°C): a simple technique for unanesthetized mice. Medical Physics 1984; 11: 833–839
   PubMed Web of Science ®Google Scholar
• Robins H. I., Dennis W. H., Neville A. J., Shecterle L. M., Martin P. A., Grossman J., Davis T. E., Neville S. R., Gillis W. K., Rusy B. F. A nontoxic system for 41.8°C WBH: results of a phase I study using a radiant heat device. Cancer Research 1985; 45: 3937–3944
   PubMed Web of Science ®Google Scholar
• Robins H. I., Longo W. L., Lagoni R. K., Neville A. J., Hugander A., Schmitt C. L., Riggs C. Phase I trial of lonidamine with whole body hyperthermia in advanced cancer. Cancer Research 1988a; 48: 6587–6592
   PubMed Web of Science ®Google Scholar
• Robins H. I., Longo W. L., Steeves R. A., Lagoni R. K., Hugander A., Neville A. J., O'Keefe S., Giese W., Schmitt C. L. A pilot study of WBH and local x-rays. International Journal of Radiation Oncology, Biology and Physics 1988b; 15: 427–431
   PubMed Web of Science ®Google Scholar
• Robins H. I., Steeves R. A., Schmitt C. L., Peterson C., Martin P. A. A hyperthermia study of differential sensitivity and thermotolerance in AKR murine leukemia and normal bone marrow cells. International Journal of Radiation Oncology, Biology and Physics 1988c; 14: 979–982
   PubMed Web of Science ®Google Scholar
• Robins H. I., Sieloff K. M., Storer B., Hawkins M. J., Borden E. C. Phase I trial of human lymphoblastoid interferon with WBH. Cancer Research 1989a; 49: 1609–1615
   PubMed Web of Science ®Google Scholar
• Robins H. I., Hugander A., Cohen J. D. Whole body hyperthermia in the treatment of neoplastic disease. Radiologic Clinics of North America 1989b; 27: 603–610
   PubMed Web of Science ®Google Scholar
• Robins H. I., Longo W. L., Steeves R. A., Cohen J. D., Schmitt C. L., Neville A. J., O'Keefe S., Lagoni R., Riggs C. Adjunctive therapy (whole body hyperthermia versus lonidamine) to total body irradiation for the treatment of favourable b-cell neoplasms: A report of two pilot clinical trials and laboratory investigations. International Journal of Radiation Oncology, Biology and Physics 1990; 18: 909–920
   PubMed Web of Science ®Google Scholar
• Rose W. C., Veras G. H., Laster W. R., Jr, Schabel F. M., Jr. Evaluation of whole-body hyperthermia as an adjunct to chemotherapy in murine tumors. Cancer Treatment Reports 1979; 63: 1311–1325
   PubMedGoogle Scholar
• Schabel F. M., Jr, Griswold D. P., Jr, Corbett T. H., Laster W. R., Jr, Mayo J. G., Lloyd H. H. Testing therapeutic hypotheses in mice and man: observations on the therapeutic activity against advanced solid tumors of man. Methods in Cancer Research, Vol. 17, V. T. De Vita, Jr, H. Busch. Academic Press, New York 1979; 3–51
   Google Scholar
• Shipley W. V., Stanley J. A., Steele G. G. Tumor size dependence in the radiation response of the Lewis lung carcinoma. Cancer Research 1975; 35: 2488–2493
   PubMed Web of Science ®Google Scholar
• Stanley J. A., Shipley W. V., Steel G. G. Influences of tumor size on hypoxic fraction and therapeutic sensitivity of Lewis lung tumor. British Journal of Cancer 1977; 36: 105–113
   PubMed Web of Science ®Google Scholar
• Steel G. G., Nill R. P., Peckman M. J. Combined radiotherapy-chemotherapy of Lewis lung carcinoma. International Journal of Radiation Oncology, Biology and Physics 1978; 4: 49–52
   PubMed Web of Science ®Google Scholar
• Steeves R. A., Robins H. I., Miller K., Martin P., Shecterle L., Dennis W. Interaction of WBH and irradiation in the treatment of AKR mouse leukemia. International Journal of Radiation Biology 1987; 52: 935–947
   Web of Science ®Google Scholar
• Teicher B. A., Rose C. M. Perfluorochemical emulsion can increase tumor radio-sensitivity. Science 1984; 223: 934–936
   PubMed Web of Science ®Google Scholar
• Teicher B. A., Crawford J. M., Holden S. A., Cathcart K. N. S. Effects of various oxygenation conditions on the enhancement by Fluosol-DA of melphalan antitumor activity. Cancer Research 1987a; 47: 5036–5041
   PubMed Web of Science ®Google Scholar
• Teicher B. A., Holden S. A., Jacobs J. L. Approaches to defining the mechanism of Fluosol-DA 20%/carbogen enhancement of melphalan antitumor activity. Cancer Research 1987b; 47: 513–518
   PubMed Web of Science ®Google Scholar
• Teicher B. A., Jacobs J. L., Kelley M. J. The influence of Fluosol®-DA on the occurrence of lung metastases in Lewis lung carcinoma and B16 melanoma. Invasion and Metastasis 1988; 8: 45–56
   PubMedGoogle Scholar
• Teicher B. A., Herman T. S., Kaufmann M. E. Interaction of PtCl4(fast black)2 with superhelical DNA and with radiation in vitro and in vivo. Radiation Research 1989a; 119: 134–144
   PubMed Web of Science ®Google Scholar
• Teicher B. A., Herman T. S., Pfeffer M. R., Alvarez Sotomayor E., Khandekar V. S. Interaction of PtCl4(fast black), with hyperthermia. Cancer Research 1989b; 49: 6208–6213
   PubMed Web of Science ®Google Scholar
• Teicher B. A., Herman T. S., Tanaka J., Eder J. P., Holden S. A., Bubley G., Coleman C. N., Frei E., III. Modulation of alkylating agents by etanidazole and fluosol-DAkarbogen in the FSaLLC fibrosarcoma and EMT6 mammary carcinoma. Cancer Research 1991; 51: 1086–1091
   PubMed Web of Science ®Google Scholar
• Vander Zee J., Van Rhoon G. C., Wike-Hooley J. L., Faithful N. S., Reinhold H. S. Whole-body hyperthermia in cancer therapy: a report of a phase I-II study. European Journal of Cancer and Clinical Oncology 1983; 19: 1189–1200
   PubMedGoogle Scholar
• Wilke A. V., Jenkins C., Milligan A. J., Legendre A., Frazier D. L. Effect of hyperthermia on normal tissue toxicity and on adriamycin pharmacokinetics in dogs. Cancer Research 1991; 51: 1680–1683
   PubMed Web of Science ®Google Scholar
• Wondergem J., Bulger R. E., Strebel F. R., Newman R. A., Travis E. L., Stephens L. C., Bull J. M. C. Effects of cis-diamminedichloroplatinum(II) combined with whole body hyperthermia on renal injury. Cancer Research 1988a; 48: 440–446
   PubMed Web of Science ®Google Scholar
• Wondergem J., Strebel F. R., Siddik Z. H., Newman R. A., Bull J. M. The effects of anesthetics on cis-platinum-induced toxicity at normal temperatures and during WBH: the influence of NaCl concentration of the vehicle. International Journal of Hyperthemia 1988b; 4: 643–654
   PubMed Web of Science ®Google Scholar
• Wondergem J., Bulger R. E., Siddik Z. H., Leygraaf J-W, Strebel F. R., Alonso M., Travis E. L., Bull J. M. C. A comparison of thermal enhancement of cis-diamminedichloroplatinum(II) induced renal and intestinal toxicities by whole body hyperthermia in the rat. International Journal of Radiation Oncology, Biology and Physics 1989; 16: 1551–1556
   PubMed Web of Science ®Google Scholar
• Wondergem J., Stephens L. C., Strebel F. R., Baba H., Ohno S., Siddik Z. H., Newman R. A., Bull J. M. Effect of adriamycin combined with whole body hyperthermia on tumor and normal tissues. Cancer Research 1991; 51: 3559–3567
   PubMed Web of Science ®Google Scholar